三城市42家医院2012-2016年抗肿瘤药应用分析

Analysis of the Utilization of Antitumor Drugs in 42 Hospitals from 3 Cities during 2012-2016

目的:分析北京、上海、成都三城市42家医院抗肿瘤药临床应用情况及趋势,为临床合理用药提供参考。方法:对北京、上海和成都三城市42家医院2012-2016年抗肿瘤药销售金额、用药频度(DDDs)等进行统计分析。结果:三城市抗肿瘤药总销售金额呈逐年上升趋势,北京销售金额在三城市中居首位,上海年均增长率最高。三城市5年抗肿瘤药销售金额排名中,免疫抑制剂他克莫司、吗替麦考酚酯均进入了各城市销售金额排名前10位。北京、上海和成都销售金额排名首位的药品分别为胸腺五肽、他克莫司和胸腺法新。抗肿瘤药各亚类中,北京、成都2012-2014年其他抗肿瘤药及辅助治疗药的销售金额均居首位,2015-2016年抗代谢药的销售金额居首位,且北京高于成都;上海2012-2016年均以抗代谢药销售金额居首位。三城市2012-2014年各抗肿瘤药亚类销售金额最高的是其他抗肿瘤及辅助治疗药,2015-2016年是抗代谢药。相关治疗药物中,免疫增强剂、免疫抑制剂和镇痛药的销售金额均排名靠前;DDDs前10名中,激素类抗肿瘤药最多,烷化剂仅环磷酰胺进入排名。结论:三城市抗肿瘤药销售金额增长趋势平稳;抗代谢药、激素类和植物来源的抗肿瘤药使用越来越多;分子靶向治疗药物有良好的应用前景。

OBJECTIVE： To analyze the clinical application and trend of antitumor drugs in 42 hospitals from Beijing, Shang- hai and Chengdu, and to provide reference for rational drug use in clinic. METHODS： The utilization of antitumor drugs in 42 hos- pitals from Beijing, Shanghai and Chengdu during 2012-2016 was analyzed statistically in respects of consumption sum, DDDs. RESULTS： The consumption sum of antitumor drugs in 3 cities, Beijing ranked the first; annual growth rate of Shanghai was the highest. In the list of consumption sum of antiturnor drugs of 3 cities in 5 years, immunosuppressive agents as tacrolimus, mycophe- nolate mofetil were among top 10 antimmor drugs in the list of consumption sum. Top 1 antitumor drug in the list of consumption sum in Beijing, Shanghai and Chengdu were thymopentin, tacrolimus and thymalfasin, respectively. Among subtype of antitumor drugs, other antitumor drugs and adjuvant drugs in Beijing and Chengdu during 2012-2014 took up the first place in the list of con- sumption sum; the consumption sum of antimetabolite during 2015-2016 occupied the first place, and that of Beijing was higher than that of Chengdu. The cost of antimetabolite in Shanghai during 2012-2016 was the highest. The consumption sum of other antitumor drugs and adjuvant drugs were the highest in 3 cities during 2012-2014; that of antimetabolite was the highest during 2015-2016. Among related drugs, immune enhancer, immunosuppressive agents and analgesics ranked the top in the list of consumption sum. Among top 10 antitumor drugs in the list of DDDs, most were antineoplastic medicine, and only cyclophosphamide among alkylat- ing agents entered the ranking. CONCLUSIONS： The growing trend of antitumor concumption sum is stable. Antimetabolite, hor- mones and plant-derived antitumor are becoming larger. Molecular targeted therapies have a good prospect for application.